08:05 AM EDT, 03/26/2026 (MT Newswires) -- BrainsWay ( BWAY ) said Thursday it has completed an additional $6 million milestone-based convertible loan to Neurolief.

The second tranche investment was triggered after the US Food and Drug Administration granted premarket approval for Neurolief's Proliv Rx system, the company said.

BrainsWay ( BWAY ) said it has invested a total of $11 million in Neurolief to date.

Under the strategic investment agreement, the company may provide additional funding, including a third tranche of up to $5 million in equity upon Neurolief reaching a specified revenue target, it added.

BrainsWay ( BWAY ) holds a call option to acquire all outstanding equity interests in Neurolief, the company said.